Management of asthma exacerbation in the emergency departments

Al-Shamrani, Abdullah; Alharbi‎, Abdulrahman; Bagais, Khalid; Alenazi, Ayed; Alqwaiee, Mansour M

doi:10.1016/j.ijpam.2019.02.001

Cited by 8 publications

(6 citation statements)

References 82 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Asthma exacerbation was diagnosed clinically by acute or subacute progressively increasing shortness of breath, cough, wheezes, chest tightness and a progressive decline in lung function that needs medical treatment. 20 All patients were atopic with eosinophilic inflammation. There were no exacerbations secondary to a bacterial infection, but viral infections could not be excluded.…”

Section: Methodsmentioning

confidence: 99%

Role of microRNA-21 and microRNA-155 as biomarkers for bronchial asthma

et al. 2020

View full text Add to dashboard Cite

MicroRNA (miRNA)-21 and miRNA-155 are important regulators of gene expression of different immunological molecules. This study aimed to investigate the role of miRNA-21 and miRNA-155 as biomarkers in asthma by comparing their serum expression levels in asthmatic patients to those in healthy controls and correlating their levels with serum IL-4. The expression levels of miRNA-21 and miRNA-155 were evaluated by quantitative RT-PCR. Serum levels of IL-4 were determined using ELISA. Asthmatic patients showed significantly higher serum miRNA-21 and miRNA-155 expression levels compared to controls. A statistically significant positive correlation between the expression levels of miRNA-21 and IL-4 serum levels in asthmatic patients was detected. Nonetheless, no correlation was detected between miRNA-155 expression and each of IL-4 and miRNA-21. A receiver operating characteristic curve analysis showed that at a cut-off value of 1.37, the sensitivity of miRNA-21 as an asthma biomarker was 100% and the specificity was 95%. At a cut-off value of 1.96, the sensitivity of miRNA-155 as an asthma biomarker was 100% and the specificity was 100%. It can be concluded that miRNA-21 and miRNA-155 are potential non-invasive biomarkers in the diagnosis of eosinophilic asthma and its response to therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Role of microRNA-21 and microRNA-155 as biomarkers for bronchial asthma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Asthma exacerbations are treated with inhaled or nebulized short-acting β agonists, such as albuterol or levalbuterol, which can initially be used every 15-20 minutes for the first hour during acute asthma exacerbation. 21 Adding ipratropium bromide, which is a short-acting muscarinic antagonist, helps reduce hospitalization rate. 22 The administration of systemic corticosteroids is also recommended by GINA, which recommends systemic corticosteroids for a number of days (usually 5-7 days) in the treatment of severe exacerbations.…”

Section: Discussionmentioning

confidence: 99%

“…Asthma exacerbation should be assessed continuously in two different stages: determination of the severity of the exacerbation by a static assessment, and evaluation of the treatment efficiency and patient's response by frequent assessments. 21 Hospitalization may be necessary following the exacerbation to monitor the patient's vital signs and administer appropriate therapy until the patient recovers.…”

Section: Discussionmentioning

confidence: 99%

Factors Predisposing Patients to Asthma Exacerbation Requiring Hospitalization: A Retrospective Study Among Lebanese Patients

Fata¹,

Jabbour²,

Sleilaty³

et al. 2021

US Respiratory &Amp; Pulmonary Diseases

View full text Add to dashboard Cite

“…Outcome yang digunakan dalam penelitian ini adalah sesak. Outcome ini merupakan parameter utama yang juga sering digunakan oleh penelitian lain seperti yang dilakukan oleh Al-Shamrani et al [13] dan Alangari [14]. Namun penelitian serupa dapat dilakukan dengan jangka waktu outcome yang lebih panjang seperti kualitas hidup [15] atau QALY [16].…”

Section: Bahasanunclassified

Study of Cost-Consequences Analysis Between Salbutamol With Aminophyllin For Exacerbation Asthma

Lorensia¹

2020

kesdok

View full text Add to dashboard Cite

Exacerbations asthma treatment can be done by giving medications therapy in the form of salbutamol and aminophyllin. This research conducted with a comparative study between two alternatives using a hospital perspective. Data were collected retrospectively based on the medical records of patients with mild-moderate exacerbations asthma who were admitted in emergency department Anwar Medika Sidoarjo Hospital during the period of January 2017 to Desember 2018. The data showing asthma exacerbations treatment effectiveness and costs were analyzed using ACER. Results of the data analysis using ACER based on total improvement of asthma sympthoms showed that in salbutamol group was Rp.2.403,75/%, and in aminophyllin group was Rp.1.688,31/%. Based on the result of study, cannot concluded which medications therapy were more cost-effective because total subject study of salbutamol and aminophyllin were different and too little. Results of the data analysis using ACER based on total improvement of asthma sympthoms showed that in salbutamol only group was Rp.2.073,18/%, and in salbutamol and corticosteroid group was Rp.1.688,31/%. Rp.2.573,40/%. Based on the result of ACER, salbutamol only group more cost-effective than salbutamol and corticosteroid group based on improvement of asthma sympthoms in mild-moderate exacerbations asthma patients in emergency department.

show abstract

Management of asthma exacerbation in the emergency departments

Cited by 8 publications

References 82 publications

Role of microRNA-21 and microRNA-155 as biomarkers for bronchial asthma

Role of microRNA-21 and microRNA-155 as biomarkers for bronchial asthma

Factors Predisposing Patients to Asthma Exacerbation Requiring Hospitalization: A Retrospective Study Among Lebanese Patients

Study of Cost-Consequences Analysis Between Salbutamol With Aminophyllin For Exacerbation Asthma

Contact Info

Product

Resources

About